Maxim analyst Anthony Vendetti upgraded Nexalin Technology (NXL) to Buy from Hold with a $5 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL:
- Nexalin receives a Notice of Allowance from USPTO for patent on DIFS
- Nexalin Technology announces initiation of patient recruitment in UCSD study
- Nexalin Technology appoints Wesley Clark to Military, Government Advisory Board
- Nexalin Technology’s HALO Clarity headset approved for use in trials by UCSD
- Nexalin appointed industry co-chair of National TBI Registry Coalition